China Human Vaccine Industry Report, 2012-2015
  • Aug./2013
  • Hard Copy
  • USD $2,600
  • Pages:132
  • Single User License
    (PDF Unprintable)       
  • USD $2,500
  • Code: ZYM045
  • Enterprise-wide License
    (PDF Printable & Editable)       
  • USD $3,900
  • Hard Copy + Single User License
  • USD $2,800
      
In the wake of China's economic growth and enhanced disease prevention awareness, Chinese human vaccine market has been expanding. In 2012, Chinese human vaccine market valued RMB10.5 billion with the lot release quantity of roughly 773 million person-portions. Restricted by China's national conditions and policies, EPI vaccines still prevail in China and Chinese EPI vaccine market is almost monopolized by state-run enterprises represented by CNBG Tiantan Biological, Biological Products Institutes in Changchun, Chengdu, Wuhan, Shanghai and Lanzhou, and Institute of Medical Biology of Chinese Academy of Medical Sciences in Kunming. In 2012, state-owned enterprises seized 81.5% of the vaccine lot release quantity in Chinese EPI vaccine market.

?Chinese EPI Vaccine Market Structure (by Enterprise Type), 2008-2012
20130209.png

However, along with the gradual relaxed access to the vaccine market, private companies have sprung up in the Extra EPI vaccine market and acquired more market share. Meanwhile, foreign counterparts occupy considerable market share by virtue of their technological and product advantages. In 2012, private and foreign-funded enterprises occupied 49.9% and 22.1% (by lot release quantity) of Chinese Extra EPI vaccine market respectively. As for human rabies vaccine and varicella vaccine markets, they mastered more than 85% of each.

In recent years, China has made some achievements in overseas vaccine markets. In 2011-2012, China’s annual human vaccine export volume remained over 90 tons (98.4 tons in 2010 was subject to the accidental H1N1 flu event), far more than 81.1 tons in 2009. Moreover, many domestic vaccine companies are still planning overseas markets aggressively.

By the end of 2012, the first batch of Hib vaccine products of Walvax Biotechnology were approved by China Customs and exported to Manila, Philippines for official marketing. Walvax Biotechnology is promoting the product registration in Russia, India, Thailand and other countries. In November 2012, Hualan Biological Engineering mailed three consecutive batches of samples for influenza virus split vaccine to WHO for testing. The company is expected to receive WHO’s spot verification certification in 2013. On March 7, 2013, Tiantan Biological obtained the production approval for polio attenuated live vaccine (liquid OPV). In accordance with the cooperation agreement with Bill & Melinda Gates Foundation in 2011, Tiantan Biological will supply OPV to United Nations International Children’s Emergency Fund (UNICEF) formally.

In addition, it is worth mentioning that the industrialization of the world's first recombinant hepatitis E vaccine (Escherichia coli) developed by Xiamen University and YangShengTang INNOVAX jointly was realized on October 27, 2012. As of the end of 2012, the lot release quantity of the product hit 90,000 person-portions.

China Human Vaccine Industry Report, 2012-2015 mainly contains the following aspects:
20120114.gif Operating environment, status quo, market supply and demand, competition pattern and development prospects of human vaccine in China;
20120114.gif Market supply and demand, competition patterns, market prices and development trends of 10 kinds of products including hepatitis B vaccine, influenza vaccine, Hib vaccine, human rabies vaccine and pneumococcal vaccine in China;
20120114.gif Import & export volume and value as well as import sources & export destinations of human vaccine in China;
20120114.gif?Operation, revenue structure, vaccine business and development trends of 11 Chinese vaccine enterprises including Tiantan Biological, Hualan Biological Engineering, Zhifei Biological, Walvax Biotechnology and Sinovac Biotech.

1. Overview of Vaccine Industry
1.1 Definition & Classification
1.2 Industry Chain

2. Overview of China Human Vaccine Industry 
2.1 Overview
2.2 Operating Environment
2.2.1 International Market
2.2.2 Policy 
2.2.3 Chinese Biopharmaceutical Market 
2.3 Status Quo
2.4 Supply & Demand
2.5 Competition Pattern
2.6 Outlook
2.7 Sales Channel

3. Human Vaccine Market Segments in China
3.1 Hepatitis B Vaccine
3.1.1 Supply & Demand
3.1.2 Competition Pattern
3.1.3 Market Price
3.2 Meningococcal Vaccine
3.2.1 Supply & Demand
3.2.2 Competition Pattern
3.2.3 Market Price
3.2.4 Market Forecast
3.3 Hepatitis A Vaccine
3.3.1 Supply & Demand
3.3.2 Competition Pattern
3.3.3 Market Price
3.3.4 Market Forecast
3.4 Influenza Vaccine
3.4.1 Supply & Demand
3.4.2 Competition Pattern
3.4.3 Market Price
3.5 Hib Vaccine
3.5.1 Supply & Demand
3.5.2 Competition Pattern
3.5.3 Market Price
3.5.4 Market Forecast
3.6 Human Rabies Vaccine
3.6.1 Supply & Demand
3.6.2 Competition Pattern
3.6.3 Market Price
3.6.4 Market Forecast
3.7 Varicella Vaccine
3.7.1 Supply & Demand
3.7.2 Competition Pattern
3.7.3 Market Price
3.8 Pneumococcal Vaccine
3.8.1 Supply & Demand
3.8.2 Competition Pattern
3.8.3 Market Price
3.9 DPT Vaccine
3.9.1 Supply & Demand
3.9.2 Competition Pattern
3.9.3 Market Situation & Forecast
3.10 Poliomyelitis Vaccine
3.10.1 Supply & Demand
3.10.2 Competition Pattern

4. Human Vaccine Import and Export in China
4.1 Export
4.1.1 Export Volume and Value
4.1.2 Export Destinations
4.2 Import
4.2.1 Import Volume and Value
4.2.2 Import Sources

5. Major Human Vaccine Producers in China
5.1 China National Biotec Group
5.1.1 Beijing Tiantan Biological Products Co., Ltd.
5.2 Hualan Biological Engineering Inc.
5.2.1 Profile
5.2.2 Operation
5.2.3 Revenue Structure
5.2.4 Gross Margin
5.2.5 Clients and Suppliers
5.2.6 R&D and Investment
5.2.7 Vaccine Business
5.2.8 Outlook and Forecast
5.3 Chongqing Zhifei Biological Products Co., Ltd.
5.3.1 Profile
5.3.2 Operation
5.3.3 Revenue Structure
5.3.4 Gross Margin
5.3.5 Clients
5.3.6 R&D and Investment
5.3.7 Outlook and Forecast
5.4 Yunnan Walvax Biotechnology Co., Ltd.
5.4.1 Profile
5.4.2 Operation
5.4.3 Revenue Structure
5.4.4 Gross Margin
5.4.5 Clients and Suppliers
5.4.6 R&D and Investment
5.4.7 Outlook and Forecast
5.5 Sinovac Biotech Ltd.
5.5.1 Profile
5.5.2 Operation
5.5.3 Revenue Structure
5.5.4 R&D and Investment
5.6 Liaoning Chengda Co., Ltd.
5.6.1 Profile
5.6.2 Operation
5.6.3 Revenue Structure
5.6.4 Gross Margin
5.6.5 Clients
5.6.6 Vaccine Business
5.7 Changchun BCHT Biotechnology Co. Ltd.
5.7.1 Profile
5.7.2 Operation
5.8 Changchun Changsheng Life Sciences Limited
5.8.1 Profile
5.8.2 Operation
5.9 Zhejiang Tianyuan Bio-Pharmaceutical Co., Ltd.
5.9.1 Profile
5.9.2 Operation
5.10 Shenzhen Kangtai Biological Products Co. Ltd.
5.10.1 Profile
5.10.2 Operation
5.11 Dalian Hissen Bio-Pharm Co., Ltd.
5.11.1 Profile
5.11.2 Operation
Classification of Vaccine
Vaccine Industry Chain
EPI Vaccine Varieties in China, 2012
Global Human Vaccine Market Scale, 2008-2012
Sales of Global Top 5 Human Vaccine Producers, 2007-2012 
R & D of Global New-type Vaccines, 2009-2012
Main M & A Cases in Global Vaccine Industry, 2005-2012 
Policies of China Vaccine Industry
Revenue and Total Profit of Biological & Biochemical Products in China, 2008-2012
Chinese Human Vaccine Market Scale, 2007-2012
Major Human Vaccine Varieties and Producers in China
Gross Margin of Major Human Vaccine Producers in China, 2007-2012
Lot Release Quantity and Share of EPI and Extra EPI Vaccines in China, 2007-2012
Chinese EPI Human Vaccine Market Share (by Lot Release Quantity), 2007-2012
Chinese Extra EPI Human Vaccine Market Share (by Lot Release Quantity), 2007-2012
R & D of New-type Human Vaccine in China, by Aug 2013
Vaccine Business of Foreign Enterprises in China, 2011-2013
Vaccine Circulation Channels in China
Lot Release Quantity of Hepatitis B Vaccine in China by Dosage Form, 2007-2012 
Hepatitis B Vaccine (CHO Cell) Suppliers and Lot Release Quantity in China, 2007-2012 
Hepatitis B Vaccine (Yeast) Suppliers and Lot Release Quantity in China, 2007-2012
Market Prices of Hepatitis B Vaccine in Some Regions of China, 2013
Meningitis Morbidity and Mortality in China, 2008-2011
Lot Release Quantity of Meningococcal Vaccine in China by Type, 2007-2012 
A-MCV Suppliers and Lot Release Quantity in China, 2007-2012 
AC-MCV Suppliers and Lot Release Quantity in China, 2007-2012 
ACYW135-MCV Suppliers and Lot Release Quantity in China, 2008-2012
Market Price of Meningococcal Vaccine in Some Regions of China, 2013
Consumption of A-MCV, AC-MCV and ACYW135-MCV in China, 2012-2015E
Hepatitis A Morbidity and Mortality in China, 2008-2011
Hepatitis A Vaccine Lot Release Quantity in China, 2007-2012 
Hepatitis A Vaccine Suppliers and Lot Release Quantity in China, 2007-2012
Market Price of Hepatitis A Vaccine in Some Regions of China, 2013 
Consumption of Hepatitis A Vaccine in China, 2012-2015E
Influenza Morbidity and Mortality in China, 2008-2011
H1N1 Influenza Morbidity and Mortality in China, 2009-2011
Lot Release Quantity of Influenza Vaccine in China, 2007-2012 
Influenza Split Vaccine Suppliers and Lot Release Quantity in China, 2007-2012 
Influenza Subunit Vaccine Suppliers and Lot Release Quantity in China, 2007-2012
Market Price of Influence Vaccine in Some Regions of China, 2013 
Hib Vaccine Lot Release Quantity in China, 2007-2012
Hib Vaccine Suppliers and Lot Release Quantity in China, 2007-2012 
Market Prices of Hib Vaccine in Some Regions of China, 2013
Sales Volume of Hib Vaccine in China, 2012-2015E 
Rabies Morbidity and Mortality in China, 2007-2011
Human Rabies Vaccine Lot Release Quantity in China, 2007-2012 
Human Rabies Vaccine Lot Release Quantity in China by Type, 2007-2012
Suppliers of Human Vero Cell Rabies Vaccine and Lot Release Quantity in China, 2007-2012 
Suppliers of Human BHK Cell Rabies Vaccine and Lot Release Quantity in China, 2007-2012 
Market Price of Human Rabies Vaccine in Some Regions of China, 2013 
Demand for Human Rabies Vaccine in China, 2012-2015E
Varicella Vaccine Lot Release Quantity in China, 2007-2012
Varicella Vaccine Suppliers and Lot Release Quantity in China, 2007-2012 
Market Price of Varicella Vaccine in Some Regions of China, 2013 
Pneumococcal Vaccine Lot Release Quantity in China, 2007-2012 
Suppliers of 7-valent and 23-valent Pneumococcal Vaccines and Lot Release Quantity in China, 2007-2012
Market Price of Pneumococcal Vaccine in Some Regions of China, 2013 
DPT Vaccine Lot Release Quantity in China, 2007-2012
Acellular DPT Vaccine Suppliers and Lot Release Quantity in China, 2007-2012 
Poliomyelitis Vaccine Lot Release Quantity in China, 2007-2012
Poliomyelitis Vaccine Suppliers and Lot Release Quantity in China, 2007-2012
Export Volume and Value of Human Vaccine in China, 2009-2012
Average Export Price of Human Vaccine in China, 2009-2012
Export Destinations of Chinese Human Vaccine, 2012
Import Volume and Value of Human Vaccine in China, 2009-2012
Average Import Price of Human Vaccine in China, 2009-2012
Import Sources of Human Vaccine in China, 2012 
Major Shareholding Companies of Tiantan Biological and Their Revenue and Net Income, 2012
Revenue and Total Profit of Tiantan Biological, 2007-2013
Revenue Breakdown of Tiantan Biological by Product, 2007-2012
Revenue Breakdown of Tiantan Biological by Region, 2007-2012
Gross Margin of Tiantan Biological by Product, 2007-2012
Tiantan Biological’s Procurement from Top 5 Suppliers and % of Total Procurement, 2007-2012
Tiantan Biological’s Revenue from Top 5 Clients and % of Total Revenue, 2007-2012
Name List and Revenue Contribution of Tiantan Biological’s Top 5 Clients, 2012
Vaccine Revenue and Gross Margin of Tiantan Biological, 2007-2012
R & D Costs and % of Total Revenue of Tiantan Biological, 2009-2012
Vaccine Lot Release Quantity and Percentage of Tiantan Biological, 2009-2012
Revenue and Total Profit of Tiantan Biological, 2012-2015E
Revenue and Total Profit of Hualan Biological, 2007-2012
Revenue Breakdown of Hualan Biological by Industry, 2007-2012
Revenue Breakdown of Hualan Biological by Product, 2007-2012
Revenue Breakdown of Hualan Biological by Region, 2007-2012
Hualan Biological’s Revenue from Top 5 Clients and % of Total Revenue, 2007-2012
Hualan Biological’s Procurement from Top 5 Suppliers and % of Total Procurement, 2007-2012
R & D Costs and % of Total Revenue of Hualan Biological, 2007-2012
Vaccine Lot Release Quantity and Percentage of Hualan Biological, 2011-2012
Vaccine Revenue and Gross Margin of Hualan Biological, 2008-2012
Revenue and Total Profit of Hualan Biological, 2012-2015E
Main Products of Zhifei Biological and Its Subsidiaries
Revenue and Profit of Zhifei Biological, 2007-2013 
Revenue Breakdown of Zhifei Biological by Product, 2010-2012
Revenue Breakdown of Zhifei Biological by Product, H1 2013
Vaccine Lot Release Quantity and Percentage of Zhifei Biological, 2011-2012
Revenue Breakdown of Zhifei Biological by Region, 2009-2013
Gross Margin of Zhifei Biological, 2008-2013
Gross Margin of Self-operated Products of Zhifei Biological, 2008-2013
Gross Margin of Agent Products of Zhifei Biological, 2008-2013
Zhifei Biological’s Revenue from Top 5 Clients and % of Total Revenue, 2008-2013
R & D Costs and % of Total Revenue of Zhifei Biological, 2008-2013
Revenue and Operating Profit of Zhifei Biological, 2012-2015E 
Industrial Layout of Walvax Biotechnology 
Revenue and Profit of Walvax Biotechnology, 2007-2013
Revenue Breakdown of Walvax Biotechnology by Product, 2007-2012
Vaccine Lot Release Quantity and Percentage of Walvax Biotechnology, 2009-2012
Revenue Breakdown of Walvax Biotechnology by Region, 2010-2012
Gross Margin of Walvax Biotechnology by Product, 2007-2012
Walvax Biotechnology’s Revenue from Top 5 Clients and % of Total Revenue, 2007-2012
Name List and Revenue Contribution of Walvax Biotechnology’s Top 5 Clients, 2012
Walvax Biotechnology’s Procurement from Top 5 Suppliers and % of Total Procurement, 2007-2012
Name List and Procurement of Walvax Biotechnology’s Top 5 Suppliers, 2011
R & D Costs and % of Total Revenue of Walvax Biotechnology, 2009-2012
On-research Vaccines of Walvax Biological, by March 31, 2013
Revenue and Profit of Sinovac Biotech, 2007-2013
Revenue Breakdown of Sinovac Biotech by Product, 2007-2013 
Vaccine Lot Release Quantity and Percentage of Sinovac Biotech, 2008-2012
R & D Costs and % of Total Revenue of Sinovac Biotech, 2007-2012
R & D Co-partners of Sinovac Biotech 
Progress of On-research Projects of Sinovac Biotech, 2012
Revenue and Net Income of Liaoning Chengda, 2007-2013
Revenue Breakdown of Liaoning Chengda by Industry, 2007-2012
Revenue Breakdown of Liaoning Chengda by Region, 2007-2012
Gross Margin of Liaoning Chengda by Industry, 2007-2012
Liaoning Chengda’s Revenue from Top 5 Clients and % of Total Revenue, 2007-2012
Name List and Revenue Contribution of Liaoning Chengda’s Top 5 Clients, 2012
Vaccine Revenue and Gross Margin of Liaoning Chengda, 2009-2012
Revenue and Operating Profit of Changchun BCHT, 2009-2012
Vaccine Lot Release Quantity and Percentage of Changchun BCHT, 2009-2012
Vaccine Lot Release Quantity and Percentage of Changchun Changsheng, 2008-2012
Main Vaccine Products of Zhejiang Tianyuan Bio-Pharmaceutical
Vaccine Lot Release Quantity and Percentage of Zhejiang Tianyuan Bio-Pharmaceutical, 2008-2012
Vaccine Lot Release Quantity and Percentage of Kangtai Biological, 2007-2012
Vaccine Lot Release Quantity and Percentage of Hissen Bio-pharm, 2009-2012
Vaccine Projects of Hissen Bio-pharm, 2012

China Animal Vaccine Industry Report, 2019-2025

Chinese animal vaccine industry showed a CAGR of 8% between 2013 and 2017, but it was depressed by the outbreak of African Swine Fever in 2018 with the market size edging down 2.5% on an annualized ba...

China Blood Product Industry Report, 2020-2026

With the dynamic adjustment in the catalog of medicines covered by national medical insurance system, the scope of clinical use of almost all blood products grows tremendously, so does the reimburseme...

China Vacuum Blood Collection Device Industry Report, 2019-2025

As laboratory medicine advances, favorable polices are issued and people live a better life and care more about their health, vacuum blood collection systems get increasingly used. In 2018, global vac...

China Human Vaccine Industry Report, 2019-2025

China has been the world’s biggest producer and consumer of human vaccines over four decades of planned vaccination, a program that has reduced incidence of multiple vaccine-targeted infectious diseas...

China Independent Clinical Laboratory Industry Report, 2019-2025

China's independent clinical laboratory industry is still in its infancy. In 2018, it only saw the penetration rate of about 5%, far below 40% or more in Europe, the United States and Japan. The main ...

Global and China Monoclonal Antibody Industry Report, 2019-2025

Global monoclonal antibody market can be presented as follows: 1. Monoclonal antibody drug market booms and is highly concentrated with the approvals for such drugs.Monoclonal antibody drugs have bee...

China Contract Research Organization (CRO) Industry Report, 2019-2025

The steadily growing global pharmaceutical industry where more and more new drugs have been approved, and the soaring spending on drug research and development in recent years, are a boon for global c...

China Blood Product Industry Report, 2019-2025

With the adjustment of the national medical insurance catalogue, the clinical application and reimbursement rate of almost all blood products have been greatly improved, and the market for blood produ...

China Human Vaccine Industry Report, 2018-2022

As the world’s largest producer of human vaccines, China has established a full-life-cycleregulatory system covering vaccine R&D, production, distribution, and vaccination. The lot release volum...

China Contract Research Organization(CRO) Industry Report, 2017-2021

Under the pressure from higher R&D costs, longer R&D cycle and lower R&D success rate in pharmaceutical industry worldwide, over 50 percent of pharmaceutical enterprises have had the devel...

China Vacuum Blood Collection Device Industry Report, 2017-2021

China’s vacuum blood collection device industry now flourishes after start-up and growth stages. Along with steady improvement in economic environment, rising per-capita disposable income, greater awa...

China Independent Clinical Laboratory Industry Report, 2017-2021

China's independent clinical laboratory industry started late, and is still in its infancy. In 2016, it only saw the penetration rate of about 4%, far below 40% or more in Europe, the United States an...

China Human Vaccine Industry Report, 2017-2021

The human vaccine industry presented the following main characteristics in 2016 in China: 1. Lot release volume of human vaccines declined.Affected by the illegal vaccine case in Mar 2016 in Shandong...

China Independent Clinical Laboratory Industry Report, 2016-2020

Owing to a large population base, uneven distribution of medical resources among regions, aging population, and continuous advance of health care reform, the Chinese independent clinical laboratory ma...

China Human Vaccine Industry Report, 2016-2020

Amid the unsafe domestic vaccine events, China’s human vaccine lot release volume in 2015 fell by 17.9% year on year to only 650 million doses,touching a 5-year low. Moreover, with the improvements in...

China Animal Vaccine Industry Report, 2016-2020

Animal vaccine is a kind of biological agent that enables inoculated animals to produce active immunity for disease prevention. In recent years, European and American animal vaccine markets have seen ...

China Blood Product Industry Report, 2016-2019

Recombinant blood products have developed for many years in foreign countries, but China’s blood products are still proteins extracted from human blood. Thus, reserves and control of plasma resources ...

China Contract Research Organization (CRO) Industry Report, 2015-2018

In recent years, China's contract research organization (CRO) industry has developed rapidly, with the market size rising from RMB8.5 billion in 2007 to RMB42.6 billion in 2014, registering a CAGR of ...

2005- www.researchinchina.com All Rights Reserved 京ICP备05069564号-1 京公网安备1101054484号